# A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

> **NCT06827613** · PHASE1,PHASE2 · RECRUITING · sponsor: **Marengo Therapeutics, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Triple Negative Locally Advanced Non-resectable Breast Cancer
- HR+, HER2-, Advanced Breast Cancer

## Interventions

- **DRUG:** STAR0602
- **DRUG:** Sacituzumab Govitecan (SG)

## Key facts

- **NCT ID:** NCT06827613
- **Lead sponsor:** Marengo Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-24
- **Primary completion:** 2027-01
- **Final completion:** 2028-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06827613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06827613, "A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06827613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*